Neoleukin Therapeutics Stock Fundamentals
NLTXDelisted Stock | USD 13.96 0.16 1.16% |
Neoleukin Therapeutics fundamentals help investors to digest information that contributes to Neoleukin Therapeutics' financial success or failures. It also enables traders to predict the movement of Neoleukin Stock. The fundamental analysis module provides a way to measure Neoleukin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neoleukin Therapeutics stock.
Neoleukin |
Neoleukin Therapeutics Company Return On Equity Analysis
Neoleukin Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neoleukin Therapeutics Return On Equity | -0.38 |
Most of Neoleukin Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neoleukin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Neoleukin Therapeutics has a Return On Equity of -0.3788. This is 98.42% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is 22.19% higher than that of the company.
Neoleukin Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neoleukin Therapeutics's current stock value. Our valuation model uses many indicators to compare Neoleukin Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neoleukin Therapeutics competition to find correlations between indicators driving Neoleukin Therapeutics's intrinsic value. More Info.Neoleukin Therapeutics is regarded third in return on equity category among related companies. It is regarded fifth in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Neoleukin Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Neoleukin Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neoleukin Therapeutics' earnings, one of the primary drivers of an investment's value.Neoleukin Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neoleukin Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neoleukin Therapeutics could also be used in its relative valuation, which is a method of valuing Neoleukin Therapeutics by comparing valuation metrics of similar companies.Neoleukin Therapeutics is currently under evaluation in return on equity category among related companies.
Neoleukin Fundamentals
Return On Equity | -0.38 | |||
Return On Asset | -0.19 | |||
Current Valuation | (35.02 M) | |||
Shares Outstanding | 2.35 M | |||
Shares Owned By Insiders | 16.46 % | |||
Shares Owned By Institutions | 45.58 % | |||
Number Of Shares Shorted | 26.4 K | |||
Price To Earning | (4.60) X | |||
Price To Book | 0.44 X | |||
EBITDA | (56.48 M) | |||
Net Income | (57.56 M) | |||
Cash And Equivalents | 116.46 M | |||
Cash Per Share | 2.73 X | |||
Total Debt | 12.07 M | |||
Debt To Equity | 0.11 % | |||
Current Ratio | 12.78 X | |||
Book Value Per Share | 34.18 X | |||
Cash Flow From Operations | (45.61 M) | |||
Short Ratio | 1.70 X | |||
Earnings Per Share | (12.28) X | |||
Price To Earnings To Growth | (0.03) X | |||
Target Price | 1.5 | |||
Beta | 1.1 | |||
Market Capitalization | 8.2 M | |||
Total Asset | 115.95 M | |||
Retained Earnings | (451.06 M) | |||
Working Capital | 88.07 M | |||
Current Asset | 289 K | |||
Current Liabilities | 1.02 M | |||
Z Score | -5.73 | |||
Net Asset | 115.95 M |
About Neoleukin Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neoleukin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neoleukin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neoleukin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |